Acadia Pharmaceuticals Soars 13.54% on Earnings Beat

On April 11, 2025, Acadia Pharmaceuticals' stock surged by 13.54% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Acadia Pharmaceuticals recently reported earnings per share of $0.20 for the quarter, surpassing the consensus estimate of $0.14 by $0.06. This positive earnings report has contributed to the recent surge in the company's stock price.

Analysts have provided a mixed outlook for Acadia Pharmaceuticals. While some analysts have maintained a "Buy" rating, others have downgraded the stock. For instance, Guggenheim recently changed its rating from "Buy" to "Neutral" and lowered its target price from $23.00 to $20.00. Despite this, the average rating from 16 analysts remains a "Buy," with a 12-month stock price forecast of $23.93, indicating a potential increase of 69.60% from current levels.

The company's stock has experienced volatility in recent weeks, with a 6.1% increase in the last trading session and a 18% loss over the past four weeks. The recent jump in share price came after President Trump announced a 90-day pause on his sweeping tariffs against non-retaliating countries, which may have positively impacted investor sentiment towards the biopharmaceutical sector.